ITeos Therapeutics Inc [ITOS] stock is trading at $10.00, down -0.20%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling.
From an analyst’s perspective:
ITeos Therapeutics Inc [NASDAQ: ITOS] stock has seen the most recent analyst activity on May 28, 2025, when Wells Fargo downgraded its rating to a Equal Weight but kept the price target unchanged to $12 for it. Previously, Wedbush downgraded its rating to Neutral on May 28, 2025, and kept the price target unchanged to $12. On May 14, 2025, downgrade downgraded it’s rating to Market Perform but maintained its price target of $9 on the stock. H.C. Wainwright downgraded its rating to a Neutral. JP Morgan downgraded its rating to a Neutral. Wells Fargo started tracking with a Overweight rating for this stock on August 13, 2024, and assigned it a price target of $31. In a note dated May 05, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $37 on this stock.
ITeos Therapeutics Inc [ITOS] stock has fluctuated between $4.80 and $18.13 over the past year. Currently, Wall Street analysts expect the stock to reach $11.25 within the next 12 months. ITeos Therapeutics Inc [NASDAQ: ITOS] shares were valued at $10.00 at the most recent close of the market. An investor can expect a potential return of 12.5% based on the average ITOS price forecast.
Analyzing the ITOS fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -4.35%, Pretax Profit Margin comes in at -3.41%, and Net Profit Margin reading is -3.74%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.21 and Total Capital is -0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.95 points at the first support level, and at 9.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.08, and for the 2nd resistance point, it is at 10.17.
Ratios To Look Out For
For context, ITeos Therapeutics Inc’s Current Ratio is 14.13. Also, the Quick Ratio is 14.13, while the Cash Ratio stands at 4.12. Considering the valuation of this stock, the price to sales ratio is 10.94, the price to book ratio is 0.68.
Transactions by insiders
Recent insider trading involved Detheux Michel, Chief Executive Officer, that happened on Jun 09 ’25 when 43882.0 shares were sold. Chief Executive Officer, Detheux Michel completed a deal on Jun 10 ’25 to sell 43883.0 shares. Meanwhile, Chief Executive Officer Detheux Michel sold 8400.0 shares on Jun 09 ’25.
